论文部分内容阅读
目的探讨产后妇女宫颈人乳头瘤病毒(HPV-DNA)分型检测联合新柏氏液基细胞学检查(TCT)在宫颈癌防治的临床价值。方法对产后4个月~1年妇女进行HPV-DNA和TCT检查。结果 1630例产妇HPV-DNA感染119例,感染率为7.30%,以高危型感染居多,主要集中在20~25岁、31~35岁年龄组。TCT异常21例中,10例宫颈病理学异常者,分别为C IN(宫颈上皮内瘤变)Ⅰ级3例,C INⅡ级4例,C INⅢ级1例,宫颈鳞癌2例。10例患者均有HPV感染。11例阴性患者,3例有HPV感染,感染率为27.27%,且年龄均在30岁以下。结论 HPV-DNA联合TCT筛查宫颈癌及癌前病变方法有利于早诊早治和HPV感染随访管理,可作为宫颈癌及癌前病变筛查的主要手段。
Objective To investigate the clinical value of detecting genital HPV-DNA in postpartum women combined with neo-Parker-based cytology (TCT) in the prevention and treatment of cervical cancer. Methods HPV-DNA and TCT were detected in women of 4 months to 1 year after delivery. Results Among 1630 maternal HPV-DNA infections, 119 cases were infected with the infection rate of 7.30%. Most of them were infected with high-risk type, mainly in 20-25 years old and 31-35 years old group. Of the 21 cases with abnormal TCT, 10 cases of abnormal cervical pathology were grade Ⅰ in CIN (cervical intraepithelial neoplasia) in 3 cases, CINⅡ in 4 cases, CINⅢ in 1 case and cervical squamous carcinoma in 2 cases. All 10 patients had HPV infection. Eleven patients were negative, three had HPV infection, the infection rate was 27.27%, and were under 30 years of age. Conclusion The combination of HPV-DNA and TCT in the screening of cervical cancer and precancerous lesions is beneficial to early diagnosis and early diagnosis and follow-up management of HPV infection, which can be used as the primary screening method for cervical cancer and precancerous lesions.